A5040147714- Psoriasis: Treatment and Pathogenesis
- Pharmaceutical studies and practices
- Health Systems, Economic Evaluations, Quality of Life
- Gastroesophageal reflux and treatments
- Pneumonia and Respiratory Infections
- Respiratory viral infections research
Frederiksberg Hospital
2023
Background A new 20-valent pneumococcal conjugate vaccine (PCV20) provides protection against 20 serotypes. The has the potential to decrease impact of diseases in society and increase health among vulnerable persons.Aim This study investigates cost-effectiveness vaccinating Danish adults different age groups risk disease with PCV20 compared 23-valent polysaccharide (PPV23) – either as PPV23 or followed by PPV23.Methods Markov model adapted setting was developed estimate clinical outcomes...
The objective of this study was to optimise the cost-effectiveness different anti-IL17 treatment sequences used in moderate-to-severe plaque psoriasis Italy and Germany over a five-year time horizon.We adjusted previously published sequence model for biologic drugs an Italian German setting, respectively. included all biologics currently available markets scope (secukinumab, ixekizumab, brodalumab bimekizumab). Real-world discontinuation rates were switches between four study. costs based on...